Sagent Pharmaceuticals Stock Return On Equity
Sagent Pharmaceuticals fundamentals help investors to digest information that contributes to Sagent Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Sagent Stock. The fundamental analysis module provides a way to measure Sagent Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sagent Pharmaceuticals stock.
Sagent |
Sagent Pharmaceuticals Company Return On Equity Analysis
Sagent Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sagent Pharmaceuticals Return On Equity | -8.0E-4 |
Most of Sagent Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sagent Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Sagent Pharmaceuticals has a Return On Equity of -8.0E-4. This is much lower than that of the sector and significantly lower than that of the Return On Equity industry. The return on equity for all United States stocks is notably higher than that of the company.
Sagent Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sagent Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sagent Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Sagent Pharmaceuticals by comparing valuation metrics of similar companies.Sagent Pharmaceuticals is currently under evaluation in return on equity category among related companies.
Sagent Fundamentals
| Return On Equity | -8.0E-4 | |||
| Return On Asset | -5.81 | |||
| Profit Margin | (6.68) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 497.53 M | |||
| Shares Outstanding | 32.44 M | |||
| Shares Owned By Insiders | 27.74 % | |||
| Shares Owned By Institutions | 76.80 % | |||
| Number Of Shares Shorted | 1.57 M | |||
| Price To Earning | 29.79 X | |||
| Price To Book | 2.81 X | |||
| Price To Sales | 2.40 X | |||
| Revenue | 318.3 M | |||
| Gross Profit | 87.74 M | |||
| EBITDA | (48.56 M) | |||
| Net Income | (21.88 M) | |||
| Cash And Equivalents | 28.96 M | |||
| Cash Per Share | 1.08 X | |||
| Total Debt | 1.62 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 2.16 X | |||
| Book Value Per Share | 7.44 X | |||
| Cash Flow From Operations | (7.52 M) | |||
| Earnings Per Share | (0.77) X | |||
| Number Of Employees | 440 | |||
| Beta | 1.7 | |||
| Market Capitalization | 613.7 M | |||
| Total Asset | 349.73 M | |||
| Retained Earnings | (122.82 M) | |||
| Working Capital | 107.94 M | |||
| Current Asset | 191.59 M | |||
| Current Liabilities | 83.66 M |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Sagent Stock
If you are still planning to invest in Sagent Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sagent Pharmaceuticals' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |